Oppenheimer & Co. Inc. Has $390,000 Position in 10x Genomics, Inc. (NASDAQ:TXG)

Oppenheimer & Co. Inc. decreased its position in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 28.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,294 shares of the company’s stock after selling 6,745 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in 10x Genomics were worth $390,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. ARK Investment Management LLC increased its holdings in 10x Genomics by 48.2% in the second quarter. ARK Investment Management LLC now owns 9,313,763 shares of the company’s stock valued at $181,153,000 after purchasing an additional 3,029,951 shares during the period. Sumitomo Mitsui Trust Holdings Inc. increased its stake in shares of 10x Genomics by 69.6% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 6,143,067 shares of the company’s stock valued at $119,483,000 after buying an additional 2,521,289 shares during the period. Deerfield Management Company L.P. Series C bought a new position in shares of 10x Genomics during the second quarter worth about $11,612,000. Price T Rowe Associates Inc. MD lifted its stake in shares of 10x Genomics by 17.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,657,227 shares of the company’s stock worth $137,257,000 after acquiring an additional 553,053 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its holdings in 10x Genomics by 3.7% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,373,212 shares of the company’s stock valued at $143,907,000 after acquiring an additional 230,145 shares during the last quarter. 84.68% of the stock is currently owned by institutional investors and hedge funds.

10x Genomics Stock Up 0.5 %

NASDAQ TXG opened at $13.38 on Friday. The company has a 50-day simple moving average of $17.73 and a two-hundred day simple moving average of $20.06. 10x Genomics, Inc. has a 12-month low of $12.95 and a 12-month high of $57.90. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of -8.75 and a beta of 1.87.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04. The firm had revenue of $151.65 million during the quarter, compared to analyst estimates of $158.84 million. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The business’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.51) earnings per share. Equities analysts expect that 10x Genomics, Inc. will post -1.4 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on TXG shares. Barclays lowered their target price on 10x Genomics from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Friday, November 1st. The Goldman Sachs Group dropped their target price on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating on the stock in a research report on Wednesday, October 30th. Morgan Stanley reduced their price target on shares of 10x Genomics from $50.00 to $46.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Stephens reiterated an “overweight” rating and set a $30.00 price objective on shares of 10x Genomics in a report on Thursday, October 10th. Finally, Leerink Partnrs upgraded 10x Genomics to a “strong-buy” rating in a research note on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, 10x Genomics has a consensus rating of “Moderate Buy” and a consensus price target of $29.19.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.